Alison Hanstead is a partner in the Intellectual Property Practice Group of the New York office.
Ms. Hanstead represents clients in complex patent and antitrust litigations and commercial disputes, in both federal and state courts.
She has significant experience with Hatch-Waxman-related litigation, and advises clients on the intellectual property and regulatory aspects of transactional matters in the pharmaceutical industry. Clients also benefit from her experience conducting due diligence investigations and drafting license agreements.
Counsel to Vertex in Hatch-Waxman patent infringement cases pending in the District of Delaware concerning Vertex's KALYDECO® tablets, a treatment for cystic fibrosis.
Counsel to Pfizer in a BPCIA patent infringement case in the District of Delaware and related PTAB proceedings concerning Pfizer's NYVEPRIA®, a treatment for neutropenia.
Counsel to Pfizer in BPCIA patent infringement cases in the District of Delaware concerning Pfizer's NIVESTYM®, a treatment for neutropenia.
Counsel to Pfizer in Hatch-Waxman patent infringement cases concerning Pfizer's DETROL LA®, a treatment for overactive bladder.
Counsel to Pfizer in Hatch-Waxman patent infringement cases concerning Pfizer's DETROL®, a treatment for overactive bladder.
Counsel to Javelin and Hospira in a Hatch-Waxman patent infringement case concerning DYLOJECT®, a nonsteroidal anti-inflammatory drug for intravenous administration.
Counsel to Novo Nordisk in Hatch-Waxman patent infringement cases concerning Novo Nordisk's VAGIFEM®, a treatment for menopause.
Counsel to Microsoft in a patent infringement case pending in the Western District of Texas against the California Institute of Technology involving transfer encoding.
Counsel to Pfizer in breach of contract disputes with NYU in New York state court concerning Pfizer's Xalkori® and Lorbrena®, which are kinase inhibitors indicated for the treatment of metastatic non-small cell lung cancer.
Trial counsel to an entertainment technology company in a breach of contract dispute.
Counsel to BTG International Limited in an antitrust class action alleging sham Hatch-Waxman patent litigation and Walker Process fraud with respect to ZYTIGA®, a treatment for prostate cancer.
Counsel to Boehringer Ingelheim in In re Aggrenox Antitrust Litigation MDL (D. Conn.) concerning antitrust challenge to a Hatch-Waxman patent settlement agreement.
Counsel to Warner Chilcott and Watson in In re Loestrin Antitrust Litigation (D. R.I.) concerning antitrust challenges to Hatch-Waxman patent settlement agreements, as well as claims of fraud on the PTO and so-called "product hopping."
Counsel to Warner Chilcott and Allergan in In re Asacol Antitrust Litigation (D. Mass.) concerning antitrust challenge to Hatch-Waxman patent settlement agreement and so-called "product hopping."
Represented a major pharmaceutical company in an arbitration concerning whether the client's product was covered by another major pharmaceutical company's patent.